EUVIMEDEUVIMED entdecken
ValidierungsstudieOpen Access

Validation of CXCL9 as a biomarker of morphoea disease state and severity through longitudinal analysis

Henry W Chen iD, Grant Barber iD, Jennifer Foster iD, Christina K Zigler iD, Jack C O'Brien, Heidi T Jacobe iD

British Journal of Dermatology · 2025

DOI: 10.1093/bjd/ljaf267 ↗

Kurz gefasst

Validierungsstudie in der Zeitschrift British Journal of Dermatology, 2025. Verfasst von Henry W Chen und 5 weiteren Autor:innen. Beteiligte Einrichtung: University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, USA. Hauptthemen laut MEDLINE: Chemokine CXCL9, Scleroderma, Localized. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Medical Student Research Fellowship, Rheumatology Research Foundation, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Morphoea disease state (active vs. inactive) is difficult to ascertain using clinical examination alone, but it is crucial to optimizing treatment. To date, no biomarkers indicative of disease state have been fully validated in morphoea.

Objectives

To better validate CXCL9 as a biomarker of morphoea disease state.

Methods

This was a prospective longitudinal cohort study of 133 people with morphoea. Morphoea activity and damage were determined with the validated Localized Scleroderma Cutaneous Assessment Tool (LoSCAT) and CXCL9 serum concentrations were measured by enzyme-linked immunosorbent assay. Analysis included measures of association of CXCL9 concentrations with clinical activity and damage scores. Published guidelines for biomarker validation were used.

Results

At baseline, CXCL9 concentration was elevated in patients with active morphoea (n = 50/81; 62%) vs. those with inactive morphoea [n = 20/52; 38% (P = 0.02)] and healthy control individuals [n = 7/25; 28% (P = 0.02)]. In the morphoea group overall, CXCL9 concentration correlated with validated activity and damage scores [modified Localized Scleroderma Skin Severity Index (mLoSSI) r = 0.43 (P < 0.001); Localized Scleroderma Skin Damage Index r = 0.52 (P < 0.001)]. Correlation of CXCL9 concentrations with damage was driven by the sclerosis subscore (r = 0.53; P < 0.001). Receiver operating characteristic analysis of cutoff calculated from healthy control participants revealed increasing sensitivity (mLoSSI > 3: 66.1%; > 10: 78.9%; > 20: 86.5%) and stable specificity (mLoSSI > 3: 58.3%; > 10: 55.6%; > 20: 51.9%) with more active disease. Baseline CXCL9 concentrations were elevated in patients with the generalized subtype of morphoea vs. all other subtypes and in adults vs. children. Multivariable longitudinal analysis corroborated positive correlations of mLoSSI and older age with CXCL9 concentration and revealed a new, positive association with musculoskeletal extracutaneous manifestations. Increases in CXCL9 concentrations predicted reactivation of morphoea activity in 73% of patients (n = 8/11) within 9 months of the increase.

Conclusions

Our findings suggest that CXCL9 serum concentrations can be used as a biomarker, in addition to clinical assessment of morphoea, to identify and predict morphoea disease state and severity.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Chemokine CXCL9Scleroderma, LocalizedHumansMaleFemaleBiomarkersLongitudinal StudiesMiddle AgedAdultSeverity of Illness IndexProspective StudiesEnzyme-Linked Immunosorbent AssayYoung AdultCase-Control StudiesAgedAdolescent

Substanzen

Chemokine CXCL9BiomarkersCXCL9 protein, human

Autor:innen und Institutionen

  • University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX, USA.
  • Duke University School of Medicine, Department of Population Health Sciences, Durham, NC, USA.

ORCID-Profile: Henry W Chen, Grant Barber, Jennifer Foster, Christina K Zigler, Heidi T Jacobe

Förderung

  • Medical Student Research Fellowship
  • Rheumatology Research Foundation
  • NIH HHS
  • NIAMS NIH HHS
  • NCRR NIH HHS
  • Pediatric Dermatology Research Alliance
  • National Institutes of Health
  • National Center for Research Resources

Zitieren

APA

Chen, H. W., Barber, G., Foster, J., Zigler, C. K., O'Brien, J. C., & Jacobe, H. T. (2025). Validation of CXCL9 as a biomarker of morphoea disease state and severity through longitudinal analysis. British Journal of Dermatology. https://doi.org/10.1093/bjd/ljaf267

Vancouver

Chen HW, Barber G, Foster J, Zigler CK, O'Brien JC, Jacobe HT. Validation of CXCL9 as a biomarker of morphoea disease state and severity through longitudinal analysis. British Journal of Dermatology. 2025. doi:10.1093/bjd/ljaf267

BibTeX
@article{Chen2025,
  author = {Chen, Henry W and Barber, Grant and Foster, Jennifer and Zigler, Christina K and O'Brien, Jack C and Jacobe, Heidi T},
  title = {Validation of CXCL9 as a biomarker of morphoea disease state and severity through longitudinal analysis},
  journal = {British Journal of Dermatology},
  year = {2025},
  doi = {10.1093/bjd/ljaf267}
}
Kostenlos starten →